Eli Lilly and Company (NYSE:LLY) Shares Bought by Little House Capital LLC

Little House Capital LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 85.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,515 shares of the company’s stock after purchasing an additional 1,158 shares during the period. Little House Capital LLC’s holdings in Eli Lilly and Company were worth $1,466,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Simon Quick Advisors LLC increased its position in shares of Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after acquiring an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $363,000. Hartline Investment Corp increased its position in shares of Eli Lilly and Company by 1.1% in the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after acquiring an additional 248 shares in the last quarter. Meritage Portfolio Management increased its position in shares of Eli Lilly and Company by 23.4% in the fourth quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock worth $3,717,000 after acquiring an additional 1,208 shares in the last quarter. Finally, WASHINGTON TRUST Co increased its position in shares of Eli Lilly and Company by 16.5% in the fourth quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after acquiring an additional 2,671 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $8.64 on Friday, hitting $733.51. The company’s stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The firm has a market cap of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a fifty day moving average price of $761.79 and a 200-day moving average price of $666.67. Eli Lilly and Company has a one year low of $380.77 and a one year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.09 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on LLY shares. Barclays lifted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Finally, DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.